Experts discuss financial considerations driving RSV treatment in pediatric patients.
August 23rd 2023EP. 1: Overview of RSV in Infants and Children
Adam Welch, PharmD, MBA, FAPhA, leads a discussion surrounding payer considerations for RSV vaccinations in children.
August 23rd 2023EP. 2: Barriers Inhibiting Optimal Pediatric RSV Treatment
Medical experts discuss current obstacles facing ideal respiratory syncytial virus (RSV) treatment strategies in children.
August 30th 2023EP. 3: Long-Term Impact of Childhood RSV
Long-term effects of pediatric RSV diagnosis are explored.
August 30th 2023EP. 4: Current Standards of Care in RSV Treatment for Children
The panel highlights the current standards of care and strategies for treating children with RSV.
September 6th 2023EP. 5: Role of Monoclonal Antibodies in RSV Prevention
Revolutionary advancements in monoclonal antibodies are considered for prevention of RSV.
September 6th 2023EP. 6: Prophylactic Use of Monoclonal Antibodies for RSV in Infants
Preemptive treatment strategies for pediatric RSV are discussed by key opinion leaders.
September 13th 2023EP. 7: Financial Impact Associated With RSV
RSV diagnosis can lead to an array of financial complications.
September 20th 2023EP. 8: Implications and Considerations Related to Reimbursement of mAbs
In their closing thoughts the panelists discuss reimbursement-related considerations surrounding mAbs.
